PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification [7]: A61K 39/395, 51/10, 47/48 // A01K 67/027, C07K 16/00, 16/28

A2

(11) International Publication Number: WO 00/02584

(43) International Publication Date: 20 January 2000 (20.01.00)

(21) International Application Number: PCT/US99/15600

(22) International Filing Date: 12 July 1999 (12.07.99)

(30) Priority Data:

60/092,672	13 July 1998 (13.07.98)	US
60/110,608	2 December 1998 (02.12.98)	US

(71) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).

(72) Inventors: THORPE, Philip, E.; 6722 Lakewood Boulevard, Dallas, TX 75214 (US). RAN, Sophia; 5840 Spring Valley Road #1612, Dallas, TX 75240 (US).

(74) Agent: FUSSEY, Shelley, P., M.; Williams, Morgan & Amerson, Suite 250, 7676 Hillmont, Houston, TX 77040 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: CANCER TREATMENT METHODS USING ANTIBODIES TO AMINOPHOSPHOLIPIDS

(57) Abstract

Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti–aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression *in vivo*. This invention therefore provides anti–aminophospholipid antibody–based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti–phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.